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Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.
Where copyrighted material is quoted, permission has been obtained to use such material.
Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.
Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.
In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory 
INTRODUCTION
Ataxia telangiectasia (AT), which results from mutations in both copies of the ATM gene, is relatively rare with an incidence of approximately only 1 in 100,000. However, the heterozygous condition which is characterized by a mutation in one copy of the gene, is thought to affect roughly 0.5-1% of the population. These individuals do not suffer from AT, however, they appear to be particularly susceptible to the induction of breast cancer by radiation. The hypothesis being examined in this project is that women who are ATM gene carriers and receive radiation therapy, generally as part of a breast conservation treatment, are at increased risk of developing a second primary breast cancer. Hence, the goal of this study is to determine whether radiation exposure resulting from the scattered dose to the contralateral breast is associated with an increased occurrence of bilateral breast cancer among women who are heterozygous for ATM. This will be accomplished through screening bilateral breast cancer patients for ATM mutations. Confirmation of this hypothesis would have important and direct implications upon patient care in that it would suggest that breast cancer patients should be tested for ATM heterozygosity. If found positive, a possible recommendation may be that these women should not be candidates for radiotherapy and other treatment modalities utilized. Alternatively, a more effective block technique with dose reduction to the contralateral breast may be implemented for these patients. This would have the positive impact upon the vast majority of patients that are not ATM carriers as they could be assured that their risk for radiation induced breast cancer is extremely low as ATM carriers may account for most breast cancers resulting exposure of the contralateral breast to radiation associated with radiotherapy.
BODY
Task 1: Month 1: Identify with Dr. Paul Tartter the bilateral breast cancer patients who fall into the two categories to be used in this study.
This was accomplished using records Dr. Tartter has assembled for bilateral breast cancer patients treated at Mount Sinai over the past 18 years.
Task 2: Month 1: Establish a procedure by which the breast cancer patients will be recruited into the study.
There was relatively easy accessibility to unilateral breast cancer patients as many of these patients were treated in the Radiation Oncology Department and continue to come to Mount Sinai periodically for follow-up visits. Arrangements were made so that when patients selected for this study arrived for their exam, an investigator was available to explain the project to the patients and obtain informed consent for participation in the study following which a nurse would draw a blood sample. A difficulty arose, however, recruiting bilateral breast cancer patients into the study as many of these patients, who were treated as long as 18 years ago, had either died, been lost to follow up or rarely visited Mount Sinai. Therefore, a alternate strategy was developed to access the bilateral patients in which paraffin embedded tissue, preferably lymph node biopsy samples, were obtained for these individuals. A collaboration was established with Dr. Ira Bleiweiss, the pathologist at Mount Sinai responsible for review of all breast cancers. Using this approach, we successfully retrieved paraffin-embedded tissue blocks from 41 bilateral patients identified by Dr. Tartter. Task 3: Month 1: Decide which regions of ATM will be subjected to analysis based upon results available in the literature at the time the project begins As of this point, there are no specific allelic hotspots or regions of ATM which have been identified for mutations. Therefore, the entire coding region of the gene is being examined.
Task 4: Months 2-32: Obtain blood samples from breast cancer patients
Blood samples were obtained from a total of 37 unilateral breast cancer patients. In addition, tissue blocks were retrieved for 41 bilateral breast cancer patients.
Task 5: Month 2: Create appropriate primers for RT-PCR and sequencing
During the period when a procedure to recruit bilateral breast cancer patients into the study was being established, efforts were also initiated to create primers for RT-PCR. As this effort was well underway by the time a decision was made to use genomic DNA obtained from paraffin embedded tissue, it was decided to complete construction of the cDNA primers and use them to screen for ATM mutations in unilateral breast cancer patients. The results of this portion of the project have been submitted for publication and a copy of this manuscript entitled "ATM heterozygosity and breast cancer: screening of 37 breast cancer patients for ATM mutations using a non-isotopic RNase cleavage-based assay" has been included in the appendix to this report.
Work was accomplished during the past year in which primers were designed and validated to amplify the exons which comprise the ATM gene. The sequences of these primers are listed in Tables 1 and 2 .
Task 6: Months 3-36: Isolate mRIMA from blood lymphocytes of patients As described, rather than isolating mRNA from blood samples, genomic DNA was isolated from pariffin-embedded biopsy tissues. To accomplish this, the ONCOR EX-WAX™ DNA Extraction Kit was used. The procedure employed was to first cut 10 sections of 5 \i thickness from a paraffin-embedded lymph node biopsy sample and place them in a 1.5 ml tube. 1 ml of 100% ethanol was added, vortexed 1 5 sec, centrifuged at 12,000 rpm 3 min, the ethanol removed and the pellet air dried. 150 \i\ of digestion solution and 50 \i\ of protein digesting enzyme solution were added and the tube incubated 4-18 hr at 50°. 100 \i\ of extraction solution was mixed and after 15 sec the tube was centrifuged 10 min at 12,000 rpm. The supernatant was removed by poking the pipette tip through the paraffin layer on top and withdrawing the supernatant, leaving the paraffin and pellet behind. 150 |al of precipitation solution was added to the supernatant, the tube inverted 3 times, 900 ^il of 100% ethanol (-20°) added and mixed. After 1 hr the tube was centrifuged for 10 min at 12,000 and the supernatant discarded. The pellet was air dried and 50 \x\ of resuspension solution added for 1 hr at 50°. RT-PCR was not necessary as genomic DNA samples were used. The first stage PCR reactions were performed using approximately 100-500 ng genomic DNA, 125 |aM dNTPs, 250 nM primers, 1 U Taq polymerase in a buffer containing 10 mM Tris.CI pH 8.3, 50 mM KCI, 1.5 mM MgCb and 0.01% gelatin and RNase free water to a total volume of 50 |_tl. The PCR reactions were performed in a Perkin Elmer 9700 Thermal Cycle at 94° for 4 min, followed by 30 cycles of 1 min at 94°, 2 min at 54° and 1.5 min at 72° and one cycle for 8 min at 72°. 10 \x\ of the first stage PCR product was used in a second series of PCR reactions using the same conditions to achieve further amplification of the region of interest and to add the T7 and SP6 promoters to the PCR products.
Task 8: Months 3-36: Use NIRCA to identify PCR products containing mutations
The 41 patients for whom exons^3, 4, 15 and 24 of ATM were amplified using PCR have been examined for mutations using a /Von-radio/'sotopic /?Nase Cleavage-based /tesay (NIRCA). Each second stage PCR product was transcribed in two reaction mixes using 2 \i\ of the PCR product, 250 nM rNTPs, 2 U of either T7 or SP6 RNA polymerase in a buffer containing 40 mM Tris.CI, pH 7.5, 7 mM MgCb, 2 mM spermidine, 25 mM NaCI and 10 mM dithiothreitol and brought to a final volume of 10 ul with RNase free H2O and incubated for 1 hr at 37°. 10 \x\ of buffer containing 80% (v/v) formamide, 25 mM NaCI, 2 mM EDTA, pH 8.0 was added to each transcription reaction. The T7 and SP6 reactions were mixed, incubated at 95° for 3 min and allowed to cool at room temperature for 1 min. 4 JJJ of the duplex reactions were mixed with 16 \x\ of RNase digestion buffer (10 mM NaCI, 10 mM Tris.CI, pH 7.5, 1 mM disodium EDTA, pH 8.0) with 0.5 ng/ml RNase A, RNase I and RNase T1 and brought to a final volume of 20 \i\. The reaction mixtures were incubated at 37° for 20 min and resolved on a 3% agarose gel run at 100 V for approximately 45 min.
Task 9:Months 3-36: Sequence all PCR products which appear to exhibit mutations
There was no evidence of any mutations in the samples that have been analyzed up to this point and therefore it has not been necessary to perform any DNA sequencing. A hallmark of this disease is great sensitivity to radiation as AT patients who were exposed to conventional radiation doses for cancer treatment developed devastating tissue necrosis [7] . The basis for this radiosensitivity has The current explanation for the function of the ATM gene product is that it has been linked to the p53 signal transduction pathway responsible for cell cycle arrest [11] following DNA damage. Several studies have revealed that cells derived from AT patients exhibit defective or delayed increases in p53 following irradiation, suggesting that normal ATM function is required for optimal transduction of the signal from the initial radiation-induced DNA damage to the modulators of the increase in p53 levels [12] . AT cells are also defective in their ability to induce downstream genes, including GADD45, p21 and MDM2 [12] . It has been shown that the AT defect is translated into abrogation of the G1, S and G2-M checkpoints of the cell cycle [1 3].
The worldwide incidence of AT is estimated at 1:40,000-1:100,000 live births [14, 15] . In contrast to the relative rarity of this disease resulting from ATM homozygosity, heterozygosity is far more common and it has been estimated that approximately 1 percent of the population possesses a mutation in one copy of this gene [16] . These heterozygotes do not manifest any outward radiation sensitivity, but, cells derived from individuals who are carriers for a mutation in this gene exhibit a slightly increased radiation sensitivity [17, 18] .
Based upon the results of epidemiologic studies, it has been suggested that ATM carriers have a 2-6 fold greater risk for cancer development and are Drumea particularly predisposed to breast cancer compared with non-carriers [19] [20] [21] . It has been estimated that 9-18 percent of all women with breast cancer may be ATM heterozygotes [22] . To address this issue, Easton [23] performed a pooled analysis of four studies [19, 20, 22, 24] from which it can suggested that AT heterozygotes are more prone to breast cancer and could account for up to13%
of breast cancer cases, with 3.8% being the best estimate. However, recent studies have cast a doubt upon this suggestion as the level of mutations detected among breast cancer patients has been consistent with only the 1 % frequency estimated for the general population [25] [26] [27] . In addition, ATM mutations have not been detected in breast cancer patients who developed unusually severe responses to radiotherapy indicating that ATM heterozygosity does not result in acute complications associated with this treatment [28] [29] [30] .
All of the studies performed to date have been accomplished using either the protein truncation test (PTT), restriction-endonuclease fingerprinting (REF) or single strand conformation polymorphism (SSCP). However, it is important to note that none of these techniques is capable of detecting all mutations [7] and it is always essential to use a series of screening methods to locate most mutations in a population. It is therefore important to employ a complementary assay with a different basis to identify mutations which had possibly gone undetected using other techniques. NIRCA represents such an alternative approach. Hence, the purpose of this study was to determine the prevalence of germline A TM mutations in breast cancer patients using NIRCA.
Drumea

Methods
Patients
Three ml peripheral venous blood samples were obtained from a hospital-based series of 37 unselected patients diagnosed with primary breast cancer treated with radiation therapy with or without chemotherapy between 1992 and 1997.
The nature of the project was discussed with each patient and signed informed consent was obtained prior to obtaining each blood sample. Patient characteristics were obtained by chart review and are presented in Table 1 .
RNA extraction and cDNA synthesis
Lymphocytes were isolated by Ficol-plaque separation. 1.5 ml Ficol was added to 3 ml of blood and centrifuged at 12000 rpm for 20 min at room temperature.
The lymphocytes layer was collected, washed with 10 ml PBS and centrifuged for 10 min, room temperature, at 12,000 rpm. To isolate RNA from the lymphocytes, 2 ml RNAzol™ (Cinna/TEL-TEST) was added to the cells, followed by addition of 100 (il of chloroform and centrifuged at 4°C for 15 min at 12,000 rpm. The supernatant was transferred to a 1. 
PCR conditions and primers
Segments of the ATM gene were amplified from aliquots of the cDNA template using sets of primer pairs. The primers were designed with the aid of Oligo-5 software (NBI, Plymouth, MN) and are listed in Table 2 (first stage primers) and 
Non-lsotopic RNase Cleavage Assay (NIRCA)
The MisMatch Detect II Non-lsotopic RNase Cleavage Assay Kit (Ambion, Austin, TX) was used to screen the samples for ATM mutations [31, 32] . Each Table 1 . cDNA copies of the extracted mRNA were produced for each sample. This approach was employed, rather than the use of genomic DNA, to avoid analysis of intronic DNA regions. The ATM open reading frame was amplified in 11 overlapping segments using nested PCR. The products of the second stage PCR reactions, all roughly 1 kb in size, were subjected to agarose gel electrophoresis and the results obtained for 3 patients using 2 sets of primers and a p53 control displayed in Fig.1 .
The PCR products that contained promoters for either the T7 or SP6 RNA polymerase were then transcribed in an in vitro system. The convention followed with this assay was linkage of the T7 promoter to the sense strand of the fragment while the SP6 promoter was attached to the antisense strand. The RNA product produced from either the sense or antisense strand was hybridized with the complementary RNA strand produced using known normal tissue not possessing an ATM mutation. In addition, for each experiment, the RNA produced from a known mutant and wild type was hybridized with RNA transcribed from a wild type DNA template to serve as positive and negative controls for this assay, respectively.
These duplexes were subjected to agarose gel electrophoresis either prior to ( Figure 2 ) or following digestion (Figure 3 ) with RNase. The basis of this screening technique is the sensitivity to cleavage with RNase of an RNA duplex Drumea containing a mismatched region [31, 32] . This heteroduplex forms when RNA produced from a PCR product possessing a mutation at a particular site is hybridized with RNA produced from a wild type DNA template. As can be seen in figure 3 , there was the appearance of two bands following digestion of the RNA duplex derived from DNA fragments containing a known mutation in the p53 gene confirming the presence of a mutation. In contrast, none of the assays performed to detect ATM mutations exhibited multiple bands indicating that there were no ATM mutations present in the breast cancer patients tested.
Drumea Discussion A series of 37 breast cancer patients was screened for germline mutations in the ATM gene. This work was accomplished using NIRCA, an assay that is complementary to the approaches which have been previously used to estimate ATM mutation frequency in breast cancer patients. No ATM mutations were detected in this study, which is consistent with the results obtained using other techniques [25] [26] [27] . Although the number of patients tested in this study was modest, our finding of no ATM mutations in a group of 37 patients provides a Figure 3 
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